Bernstein reiterates Summit Therapeutics stock Underperform on trial concerns By Investing.com

Bernstein reiterated an Underperform rating on Summit Therapeutics with a $7.70 price target, implying roughly 56% downside from the current $17.54 share price. The firm sees limited read-through from Akeso’s 0.66 HARMONi-6 overall survival hazard ratio to Summit’s global HARMONi-3 trial, citing major population and design differences that could make HARMONi-3 results non-statistically significant. The piece reinforces a mixed analyst backdrop, but the core takeaway is a cautious-to-bearish view on Summit’s ivonescimab program.

Analysis

The market is still treating this as a single-drug readout, but the real setup is a dispersion trade between trial-design quality and sentiment-driven extrapolation. The key second-order issue is not whether ivonescimab works in one population; it is whether investors are willing to underwrite a global label expansion without cleaner external validity. That creates asymmetric downside for SMMT because the stock is priced for a broad oncology platform, while the evidentiary bar for non-China NSCLC remains materially higher than the current narrative implies.

The competitive implication is that MRK may benefit less from direct share capture than from relative credibility: every incremental doubt around SMMT raises the value of established, globally validated checkpoint/oncology franchises. If HARMONi-3 fails to deliver a statistically clean signal, the multiple compression on SMMT could be rapid and nonlinear over days to weeks, because the stock has already re-rated on expectation rather than earnings power. The overvaluation gap versus fair value suggests there is limited fundamental support to absorb a disappointment.

The contrarian view is that the bearish consensus may be underestimating optionality if global trial data come in merely “good enough” rather than spectacular. In that case, the stock could remain rangebound rather than collapse, because biotech investors often pay up for even modest probability of label breadth. But that is a lower-probability path versus the current setup, where the downside skew is larger than the upside from an incremental positive surprise.

Key Decisions for Investors

• Initiate/maintain a short SMMT position into any pre-data strength; thesis is multiple compression if HARMONi-3 does not clear a clean statistical bar. Time horizon: 2-8 weeks. Risk/reward favors 2-3x downside to upside if the stock rerates toward analyst fair value.
• For defined risk, buy SMMT put spreads centered 1-3 months out; structure for a post-catalyst vol crush but preserve payoff on a sharp gap-down. Prefer strikes that target a move back toward the low-teens or single-digits.
• Pair trade: long MRK / short SMMT as a relative-quality hedge against sector beta. This isolates trial-risk dispersion; if the market rotates back to proven franchises on biotech uncertainty, the pair should outperform outright shorts.
• Avoid chasing the bullish side in SMMT until the market has digested full global-trial comparability disclosures. If long, keep position size small and use hard stops; the asymmetry is unfavorable before the next catalyst.
• If HARMONi-3 data disappoint, use the event to cover shorts only after the initial 24-72 hour volatility window; biotech downside often overreacts immediately, but follow-through depends on whether the miss is statistical or merely interpretive.